Skip to content
Companies

Contamination Source Identification

RNA sequencing test that identifies active infections

Raised to date

$2.1M

of $2.5M offered across 1 Form D filing

Still open
$405K
Investors
16
Last filed
Apr 9, 2026

About

Contamination Source Identification, Inc. (CSI-Dx) is a Pennsylvania molecular diagnostics company that develops an RNA-sequencing test for identifying active infections. The CSI-Dx test directly isolates and identifies bacterial, viral, and other pathogenic microorganisms present in a clinical sample by detecting pathogenic RNA. Current validation work focuses on identifying prosthetic joint infections and determining the causative agents of sepsis. The company is led by CEO Gary Shope alongside R&D and bioinformatics leadership drawn from microbial genomics research.

An untargeted sequencing assay that identifies whatever pathogens are actively present in a sample rather than testing for a preselected panel of organisms, so co-infections that targeted tests miss can still be detected.

Funding

  • Security to be acquiredFiled Apr 9, 2026Form D/A
    $2.1M/ $2.5M

Product

CSI-Dx test

Clinical diagnostic test

A genomic sequencing diagnostic test that isolates and identifies active bacterial, viral, and other pathogenic microorganisms in a clinical sample by detecting pathogenic RNA.

  • Untargeted detection — no predefined organism panel
  • RNA-based, so it reports active rather than merely present organisms
  • Detects bacterial, viral, and other pathogenic microorganisms in one assay

Built for

Physicians and clinical care teams treating suspected infections, particularly orthopedic surgeons managing prosthetic joint infections and hospital clinicians managing sepsis

People on file